东北制药(000597) - 2015 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2015 was ¥1,052,532,815.37, a decrease of 9.52% compared to ¥1,163,255,996.09 in the same period last year[8] - The net profit attributable to shareholders was -¥30,972,134.27, representing a decline of 148.48% from ¥63,890,969.39 in the previous year[8] - The net cash flow from operating activities was -¥57,412,257.33, a decrease of 95.86% compared to -¥29,312,775.59 in the same period last year[8] - The basic earnings per share were -¥0.07, down 136.84% from ¥0.19 in the previous year[8] - Net profit for the period was -30.50 million yuan, a decrease of 147.22% compared to the previous year, mainly due to a net gain of 83 million yuan from the relocation of the northern plant last year[15] - The estimated cumulative net profit for the year is projected to be between -75 million and 78.38 million yuan, a decrease of 195.69% to 157.41% compared to the previous year[17] - The basic earnings per share are expected to be between -0.16 and 0.24 yuan, a decrease of 166.67% to 137.50% compared to the previous year[17] Assets and Shareholder Information - Total assets at the end of the reporting period were ¥8,926,028,444.80, an increase of 4.12% from ¥8,572,868,594.30 at the end of the previous year[8] - The net assets attributable to shareholders decreased by 1.16% to ¥2,633,383,329.78 from ¥2,664,307,475.52 at the end of the previous year[8] - The total number of ordinary shareholders at the end of the reporting period was 44,989[11] - The largest shareholder, Northeast Pharmaceutical Group Co., Ltd., held 21.46% of the shares, totaling 101,876,701 shares[11] Cash Flow and Investments - The company received tax refunds amounting to 7.61 million yuan, an increase of 73.32% compared to the previous year, mainly due to the receipt of export tax rebates[15] - Cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets was 157.53 million yuan, an increase of 90.95% compared to the previous year, primarily due to increased payments for relocation[15] - Cash received from borrowings was 1,271.67 million yuan, an increase of 30.95% compared to the previous year, mainly due to the increase in long-term borrowings[15] Other Financial Activities - The company reported non-operating income of ¥1,778,937.01 during the reporting period[9] - The company did not engage in any repurchase transactions during the reporting period[12] - The company did not hold any other listed company shares during the reporting period[20] Accounts Receivable and Current Assets - Accounts receivable at the end of the period amounted to 947.52 million yuan, an increase of 33.19% compared to the beginning of the year, primarily due to the expansion of the sales scale of formulation products[15] - Other current assets at the end of the period were 115.81 million yuan, an increase of 110.39% compared to the beginning of the year, mainly due to the addition of 60 million yuan in financial products[15] Long-term Borrowings - Long-term borrowings at the end of the period reached 280 million yuan, an increase of 180% compared to the beginning of the year, primarily due to the addition of 180 million yuan in new long-term borrowings[15]